Daily Stock Analysis, GASL, Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia., priceseries

Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.. Daily Stock Analysis
Stock Information
Open
8.30
Close
8.28
High
8.33
Low
7.96
Previous Close
8.16
Daily Price Gain
0.12
YTD High
8.82
YTD High Date
Jan 18, 2019
YTD Low
4.67
YTD Low Date
Jan 2, 2019
YTD Price Change
2.66
YTD Gain
47.33%
52 Week High
27.79
52 Week High Date
Jul 10, 2018
52 Week Low
4.08
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-11.58
52 Week Gain
-58.31%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 12. 2017
17.58
Oct 2. 2017
21.65
14 Trading Days
23.18%
Link
LONG
Oct 31. 2017
22.57
Nov 13. 2017
24.93
9 Trading Days
10.47%
Link
LONG
Dec 20. 2017
22.24
Jan 18. 2018
29.02
18 Trading Days
30.48%
Link
LONG
Apr 10. 2018
17.90
May 3. 2018
20.28
17 Trading Days
13.28%
Link
LONG
May 8. 2018
21.86
May 23. 2018
23.39
11 Trading Days
7.00%
Link
LONG
Jan 4. 2019
6.45
Jan 22. 2019
7.89
11 Trading Days
22.38%
Link
LONG
Feb 13. 2019
7.04
Feb 26. 2019
7.48
8 Trading Days
6.18%
Link
Company Information
Stock Symbol
GASL
Exchange
NASDAQ
Company URL
http://www.galectintherapeutics.com
Company Phone
678-620-3186
CEO
Peter G. Traber
Headquarters
Georgia
Business Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA 30071
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001133416
About

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.